| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $499.05M | ||||
| Company | Location | Date | Amt. (M) | Details |
| AdvanDx Inc. | Woburn, Mass. | 9/18 | $15 | AdvanDx closed a $15M Series C financing round from bioMerieux SA, LD Pensions and SLS Venture |
| Aldagen Inc. | Durham, N.C. | 9/13 | $9 | Aldagen pulled in another $9M in a Series C, bringing the total riased to $23M; new investors were Tullis-Dickerson and CNF Investments LLC; existing investors were Herbert Venture Partners LLC and Intersouth Partners |
| Altheus Therapeutics Inc. | Oklahoma City | 9/19 | $3.6 | Altheus secured $3.6M in a round led by Prolog Ventures, with participation from the Oklahoma Seed Capital Fund and Oklahoma Equity Partners |
| Amyris Biotechnologies | Emeryville, Calif. | 9/19 | $70 | Amyris raised $70M in a Series B round led by Duff Ackerman & Goodrich Ventures; other investors were Khosla Ventures, Kleiner Perkins Caufield & Byers and TPG Ventures |
| Bar Harbor BioTechnology Inc. | Trenton, Maine | 9/5 | ND | Bar Harbor closed a Series A round led by Borealis Ventures with participation by Village Ventures |
| BioMicro Systems Inc. | Salt Lake City | 9/27 | $5.5 | BioMicro raised $5.5M in a Series B financing; investors included vSpring, Nanostart AG and Staley Capital Advisors Inc. |
| Cellerix SL | Madrid | 9/20 | €27.2 ($40) | Cellerix raised $40M in a Series B led by Life Science Partners and Ventech; other investors were Roche Venture Fund, Novartis Venture Fund, Genera Biopartners, Genetrix Group and others |
| Corium International Inc. | Menlo Park, Calif. | 9/27 | $25.1 | Corium raised $25.1M in a Series C financing led by Essex Woodlands Health Ventures; it included participation by Quantum Technology Partners, Aphelion Capital and an unnamed strategic investor |
| Diffusion Pharmaceuticals LLC | Charlottesville, Va. | 9/28 | $4.5 | Diffusion raised $4.5M in a private placement |
| Enobia Pharma Inc. | Montreal | 9/11 | C$40.1 ($38) |
Enobia closed a Series B financing that will bring the company $38M over the next two years; investors are OrbiMed Advisors LLC, CTI Life Sciences Fund, Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000 |
| F-star | Vienna, Austria | 9/10 | €6 ($8.3) | F-star raised $8.3M in a Series A financing with Aescap Venture and Atlas Venture |
| Ganymed Pharmaceuticals AG | Mainz, Germany | 9/18 | €3.5 ($5) | Ganymed raised another $5M in the second closing of its Series C financing, bringing the total raised to $50.7M; it was fully subscribed by ATS Beteiligungsverwaltung GmbH |
| GenomeQuest Inc. | Westborough, Mass. | 9/24 | $4 | GenomeQuest secured an additional $4M in venture funding; Mosaix Ventures led the Series B round, with participation from Cross Atlantic Partners, Milestone Venture Partners and Societe Generale Asset Management Alternative Investments |
| GlobeImmune Inc. | Louisville, Colo. | 9/26 | $41.2 | GlobeImmune raised $41.2M in a Series C round led by Wexford Capital LLC; other investors were Celgene Inc., Mellon Family Investment Co., Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Medica Venture Partners, Adams Street Partners, Biogen Idec Inc., Pac-Link Bioventures China Investment and Development, Yasuda Enterprise Development, Partners Healthcare and GC&H Investments |
| Hyperion Therapeutics Inc. | South San Francisco | 9/5 | $40 | Hyperion raised $40M in a Series B financing led by Sofinnova Ventures, and included investments from Highland Capital Partners, New Enterprise Associates and WRF Capital |
| Lectus Therapeutics Ltd. | Cambridge, UK | 9/5 | £3 ($6.05) | Lectus secured a $6.05M investment from the Wellcome Trust |
| Nile Therapeutics Inc. | Berkeley, Calif. | 9/18 | $20 | Nile raised $20M in its first round just before merging with public shell company SMI Inc.; investors were RIT Capital Partners plc, Life Science Capital Master Fund, and other institutional investors; Riverbank Capital Securities Inc. acted as placement agent |
| OpGen Inc. | Madison, Wis. | 9/12 | $23.6 | OpGen raised $23.6M in its first major venture capital round led by CHL Medical Partners, Highland Capital Partners and Versant Ventures; Mason Wells also participated |
| Pearl Therapeutics Inc. | Redwood City, Calif. | 9/6 | $15.5 | Pearl raised $15.5M in its first round co-led by New Leaf Ventures and Clarus Ventures, with participation from 5AM Ventures |
|
Proteon Therapeutics Inc. |
Waltham, Mass. | 9/6 | $12 | Proteon raised $12M in a second round |
| Sagent Pharmaceuticals Inc. | Schaumburg, Ill. | 9/27 | $53 | Sagent closed a $53M Series A financing from Vivo Ventures |
| Sequel Pharmaceuticals Inc. | San Diego | 9/27 | $20 | Sequel raised $20M in a Series A round; investors were Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners and Skyline Ventures; Sequel is a spin-out of NovaCardia Inc., recently acquired by Merck & Co. Inc. |
| Trophos SA | Marseille, France | 9/4 | €8.5 ($11.6) | Trophos raised $11.6M in a Series C financing led by OTC Asset Management, and included CM-CIC Capital Prive, Society General Asset Management, Viveris Management, Turenne Capital Partners, Blue Medial and the Association Francaise contre les Myopathies |
| Vital Therapies Inc. | San Diego | 9/12 | $28.1 | Vital Therapies completed a $28.1M Series C round led by Versant Ventures, and included participation by Delphi Ventures, HBM BioMed China, DFJ DragonFund China, MedVenture Associates, Valley Ventures, Toucan Capital and and Heights Capital |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International.ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.